Delivery Order 36F79719D0224-36C26023F0110
Award Date 12/31/22
Potential Completion Date 12/30/23
Potential Value $426K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98108, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $198,704.64 delivery order to Horizon Therapeutics USA Inc. under the Pharmaceuticals and Drugs Federal Supply Schedule contract (FSS-61-IB). The firm fixed price order is for the purchase of PEGLOTICASE (KRYSTEXXA) 8MG/ML 75987-0080-10, with a completion date of November 30, 2022. The contract has no set-aside designation and calls for the delivery of pharmaceutical products to...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed-price delivery order to Horizon Therapeutics USA, Inc. for the specialty pharmaceutical KRYSTEXXA 8MG. The $55,903.32 order is placed against Horizon's existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). This delivery order will provide the VA with pegloticase injections to treat chronic gout in eligible veterans through...
- This delivery order for $55,903.32 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 to Horizon Therapeutics USA Inc. against the company's Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The firm fixed price order, with no set-aside designation, is for the medication KRYSTEXXA 8MG and aims to supply VHA hospitals and clinics in La Vergne, Tennessee with this orphan disease treatment through...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a firm fixed price delivery order valued at seventy-one thousand eight hundred eighty-five dollars and sixteen cents ($71,885.16) to Horizon Therapeutics USA Inc. under the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The order is to provide KRYSTEXXA 8MG for the treatment period of December 27, 2023 through December 29, 2023 and will be performed in La Vergne,...
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Horizon Therapeutics USA Inc. for the drug KRYSTEXXA 8MG/ML VIAL. The order is placed against Horizon's pre-existing General Services Administration (GSA) Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The order has a firm fixed price of $74,537.76 and a completion date of May 31, 2024. Horizon Therapeutics USA Inc. is a global biotechnology...
- This is a firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Horizon Therapeutics USA Inc., a global biotechnology company, under the company's existing Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The $37,268.88 award is for the delivery of KRYSTEXXA 8MG, a specialty medication used to treat chronic gout, to support healthcare services for veterans. This delivery order is placed against Horizon's $31.375 million...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded Horizon Therapeutics USA Inc. a $71,885 delivery order against the company's Pharmaceuticals and Drugs Federal Supply Schedule contract. The delivery order is for KRYSTEXXA 8MG to be provided between September 29 and October 3, 2023 at Horizon's facility in La Vergne, Tennessee. The contract utilizes firm fixed pricing and does not appear to include any set-aside designations. ...
- The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order for KRYSTEXXA 8MG to the prime contractor, Horizon Therapeutics USA, Inc. This order, valued at $74,537.76, was placed against Horizon's existing Multiple Award Schedule (MAS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The delivery order has an April 17, 2024 completion date and will provide the specialized orphan drug to VHA hospitals and clinics across the country...
- This is a $93,172.20 firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) to Horizon Therapeutics USA, Inc. for the drug KRYSTEXXA 8MG. The order was placed against Horizon's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB) with the VA, which has an expiration date of August 2025. Horizon also holds an $18 million Blanket Purchase Agreement (BPA) against the same Pharmaceuticals and Drugs Schedule, covering the procurement of...
- This is a $65,686.15 firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Horizon Therapeutics USA Inc. under the company's $25 million Multiple Award Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The order is for KRYSTEXXA 8MG/ML, a specialty pharmaceutical used to treat chronic gout. Horizon Therapeutics is a global biotechnology firm that provides critical medications to support healthcare services for veterans through the VA's Veterans...